Deutsche Says Anacor (ANAC) Tavaborole Numbers are Solid, Hinges on 2nd Phase 3 Results
Tweet Send to a FriendGet Alerts ANAC Hot Sheet
Price: $5.47 --0%
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 1 | Down: 2 | New: 2
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 1 | Down: 2 | New: 2
Trade ANAC Now!
Anacor Pharmaceuticals (Nasdaq: ANAC) is getting slammed amid new tavaborole phase 3 data, the Company's key pipeline candidate for the treatment of onychomycosis (nail fungus).
Deutsche Bank issued comments on the results. The firm said, "By comparison, Penlac – the first and only approved topical treatment for this indication – achieved peak sales of $300M on a worldwide basis ($120M in the US) prior to the loss of exclusivity in 2006, despite a 5.5-8.5% clinical cure rate (40% mycological cure rate) and a restrictive label, which required debridement as adjunctive therapy. As for perhaps the most important comparator, Valeant recently reported clinical cure rate of 15.2- 17.8% (mycological cure rate of 23.4-26.4%) in its Ph 3 topical onychomycosis program for IDP-108 (efinaconazole, May 26 FDA action date), which is approximately a year ahead of tavaborole in development. Hence, while not exactly apples-to-apples – given different patient inclusion criteria – Valeant’s clinical cure looks better but Anacor’s mycological cure rate looks superior."
On its call, Anacor said that the patient population may have been older and less healthy versus Valeant's (NYSE: VRX) phase 3 trials. The first phase 2 also took place in the U.S. and Mexico, with Mexico providing weaker results during the phase 2 trials of tavaborole. The second phase 3 will take place in the U.S and Canada.
Deutsche also said that if the second phase 3 has similar results to the first, tavaborole should be commercially viable.
Deutsche has a Buy rating on Anacor with price target of $11.
For an analyst ratings summary and ratings history on Anacor Pharmaceuticals click here. For more ratings news on Anacor Pharmaceuticals click here.
Shares of Anacor Pharmaceuticals closed at $5.17 yesterday, with a 52 week range of $4.50-$7.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Deutsche Bank issued comments on the results. The firm said, "By comparison, Penlac – the first and only approved topical treatment for this indication – achieved peak sales of $300M on a worldwide basis ($120M in the US) prior to the loss of exclusivity in 2006, despite a 5.5-8.5% clinical cure rate (40% mycological cure rate) and a restrictive label, which required debridement as adjunctive therapy. As for perhaps the most important comparator, Valeant recently reported clinical cure rate of 15.2- 17.8% (mycological cure rate of 23.4-26.4%) in its Ph 3 topical onychomycosis program for IDP-108 (efinaconazole, May 26 FDA action date), which is approximately a year ahead of tavaborole in development. Hence, while not exactly apples-to-apples – given different patient inclusion criteria – Valeant’s clinical cure looks better but Anacor’s mycological cure rate looks superior."
On its call, Anacor said that the patient population may have been older and less healthy versus Valeant's (NYSE: VRX) phase 3 trials. The first phase 2 also took place in the U.S. and Mexico, with Mexico providing weaker results during the phase 2 trials of tavaborole. The second phase 3 will take place in the U.S and Canada.
Deutsche also said that if the second phase 3 has similar results to the first, tavaborole should be commercially viable.
Deutsche has a Buy rating on Anacor with price target of $11.
For an analyst ratings summary and ratings history on Anacor Pharmaceuticals click here. For more ratings news on Anacor Pharmaceuticals click here.
Shares of Anacor Pharmaceuticals closed at $5.17 yesterday, with a 52 week range of $4.50-$7.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Analyst Sees Potential for Omeros' (OMER) OMS824 as FDA Gives Clearance
- Topeka Capital Starts Spansion (CODE) at Buy
- Goldman Sachs Downgrades Aixtron (AIXG) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Deutsche Bank
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
